Biosimilar Year In Review: Regulatory Achievements And Future Aspirations
Industry Stakeholders Share Their Most Notable Biosimilar Regulatory Developments In 2024
This year, regulators questioned the US interchangeability designation and the need for comparative efficacy trials, while finding ways to promote biosimilar development and accessibility. Will this momentum continue in 2025? Generics Bulletin spoke to experts from across the industry to hear their views.
